MeiraGTx Holdings (MGTX) Net Margin (2019 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Net Margin came in at 20.02% in Q4 2025, up 20421.0% YoY from N/an in Q4 2024, and up 100.16% on a QoQ basis from 12320.24% in Q3 2025.
Powered by 
Analysis
MeiraGTx Holdings (MGTX) Net Margin (2019 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 7 years of Net Margin data on file, last reported at 20.02% in Q4 2025.
- Quarterly Net Margin rose 20421.0% year-over-year to 20.02% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 113.23% (up 33086.0% YoY) and the FY2025 annual result came in at 140.31%, up 30379.0% from the prior year.
- Net Margin climbed to 20.02% in Q4 2025, from 12320.24% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 990.93% in Q4 2023 to a low of 17241.13% in Q2 2024.
- A 5-year average of 2007.64% and a median of 513.97% in 2021 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2024 — Net Margin plunged 1640551 bps — and 2025, when it surged 1619006 bps.
- Tracing MGTX's Net Margin over 5 years: stood at 47.1% in 2021, then surged by 1197 bps to 516.51% in 2022, then surged by 92 bps to 990.93% in 2023, then sank by 119 bps to 184.19% in 2024, then surged by 111 bps to 20.02% in 2025.
- The last three Net Margin figures came in at 20.02% (Q4 2025), 12320.24% (Q3 2025), and 1051.07% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 74.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 74.44% |
| Dec 31, 2025 | 20.02% |
| Sep 30, 2025 | -12,320.24% |
| Jun 30, 2025 | -1,051.07% |
| Mar 31, 2025 | -2,075.86% |
| Dec 31, 2024 | -184.19% |
| Sep 30, 2024 | -360.49% |
| Jun 30, 2024 | -17,241.13% |
| Mar 31, 2024 | -2,932.86% |
| Dec 31, 2023 | 990.93% |
| Sep 30, 2023 | -868.06% |
| Jun 30, 2023 | -835.62% |
| Mar 31, 2023 | -910.74% |
| Dec 31, 2022 | 516.51% |
| Sep 30, 2022 | -774.17% |
| Jun 30, 2022 | -315.76% |
| Mar 31, 2022 | -551.13% |
| Dec 31, 2021 | -47.10% |
| Sep 30, 2021 | -373.42% |
| Jun 30, 2021 | -392.61% |